RxDoctor Payments Data

Kristy Bowers

Adult Health · Knoxville, TNNPI 1629450390

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.5% of the total across 342 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 55 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,536 and has fallen 98.7% since, to $33 in 2025. Among adult health clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,822in general payments, 2019–2025

Across 342 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$721
  • Novartis$668
  • Seagen Inc.$562
  • AstraZeneca$458
  • Merck$437
  • Pfizer$401
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$6,44895%
  • Education$3745%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,822 in reported general payments places this provider in the 90th percentile of 352 adult health providers in Tennessee.

See all adult health providers in Tennessee

Medicare billing

Part B allowed, 2024
$6,032
Medicare patients
59
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$27,173
XareltoRivaroxaban14$17,940
Anastrozole34$794
Letrozole20$480
Acyclovir16$257
Tramadol Hcl21$211
Warfarin Sodium11$147
Pantoprazole Sodium11$100
Alendronate Sodium12$76
Zolpidem Tartrate12$60
Azithromycin11$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$401$27,17332 claims
Johnson & JohnsonXarelto$721$17,94014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 352 adult health providers in Tennessee.

Other adult health in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →